北京时间2024年10月30日,生物制药公司蓝图医药(Blueprint Medicines Corporation,股票代码BPMC)盘中股价大涨13.54%,引发市场广泛关注。
分析人士认为,推动BPMC股价大涨的主要原因是该公司上调了其胃肠道癌症药物AYVAKIT在2024财年的净产品收入预期。BPMC目前预计,2024年AYVAKIT的全球净产品收入约为4.75亿至4.8亿美元,较之前的4.35亿至4.5亿美元有所增长。
该公司表示,上调预期的主要原因是基于接受AYVAKIT治疗的患者人数持续增加、患者合规性和其他业绩因素持续向好,以及美国以外地区的销售业绩强于预期。AYVAKIT作为蓝图医药的重磅产品,收入预期的上调无疑令投资者对该公司的长期发展前景更加看好,从而推动股价走高。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.